News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
699,776 Results
Type
Article (39731)
Company Profile (247)
Press Release (659798)
Multimedia
Podcasts (51)
Webinars (12)
Section
Business (204188)
Career Advice (2008)
Deals (35422)
Drug Delivery (95)
Drug Development (81051)
Employer Resources (172)
FDA (16189)
Job Trends (14864)
News (345225)
Policy (32543)
Tag
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (86)
Alliances (49446)
ALS (93)
Alzheimer's disease (1382)
Antibody-drug conjugate (ADC) (132)
Approvals (16186)
Artificial intelligence (261)
Autoimmune disease (22)
Automation (16)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (175)
Bladder cancer (78)
Brain cancer (27)
Breast cancer (291)
Cancer (2307)
Cardiovascular disease (179)
Career advice (1677)
Career pathing (30)
CAR-T (153)
Cell therapy (432)
Cervical cancer (20)
Clinical research (66067)
Collaboration (853)
Company closure (2)
Compensation (557)
Complete response letters (19)
COVID-19 (2590)
CRISPR (41)
C-suite (249)
Cystic fibrosis (101)
Data (2297)
Decentralized trials (2)
Denatured (19)
Depression (44)
Diabetes (275)
Diagnostics (6378)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (102)
Drug shortages (25)
Duchenne muscular dystrophy (96)
Earnings (86981)
Editorial (39)
Employer branding (21)
Employer resources (146)
Events (112613)
Executive appointments (737)
FDA (17552)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (764)
Gene editing (109)
Generative AI (19)
Gene therapy (308)
GLP-1 (716)
Government (4427)
Grass and pollen (4)
Guidances (150)
Healthcare (18818)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (121)
Indications (29)
Infectious disease (2734)
Inflammatory bowel disease (143)
Inflation Reduction Act (8)
Influenza (52)
Intellectual property (97)
Interviews (312)
IPO (16522)
IRA (40)
Job creations (3633)
Job search strategy (1422)
Kidney cancer (10)
Labor market (43)
Layoffs (475)
Leadership (17)
Legal (7910)
Liver cancer (76)
Lung cancer (324)
Lymphoma (156)
Machine learning (9)
Management (58)
Manufacturing (322)
MASH (73)
Medical device (13382)
Medtech (13387)
Mergers & acquisitions (19468)
Metabolic disorders (702)
Multiple sclerosis (82)
NASH (16)
Neurodegenerative disease (91)
Neuropsychiatric disorders (27)
Neuroscience (1929)
NextGen: Class of 2025 (6512)
Non-profit (4480)
Now hiring (40)
Obesity (371)
Opinion (204)
Ovarian cancer (80)
Pain (91)
Pancreatic cancer (88)
Parkinson's disease (150)
Partnered (21)
Patents (241)
Patient recruitment (115)
Peanut (46)
People (57338)
Pharmaceutical (63)
Pharmacy benefit managers (19)
Phase I (20579)
Phase II (29102)
Phase III (21669)
Pipeline (1344)
Policy (146)
Postmarket research (2563)
Preclinical (8755)
Press Release (64)
Prostate cancer (107)
Psychedelics (30)
Radiopharmaceuticals (246)
Rare diseases (382)
Real estate (5907)
Recruiting (65)
Regulatory (22321)
Reports (47)
Research institute (2320)
Resumes & cover letters (349)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (70)
Series A (131)
Series B (87)
Service/supplier (11)
Sickle cell disease (52)
Special edition (16)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3580)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (48)
The Weekly (30)
Vaccines (697)
Venture capitalists (42)
Weight loss (236)
Women's health (36)
Worklife (16)
Date
Today (126)
Last 7 days (927)
Last 30 days (3045)
Last 365 days (32429)
2025 (11664)
2024 (35219)
2023 (40078)
2022 (51173)
2021 (55711)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32110)
2016 (31483)
2015 (37554)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (718)
Alabama (54)
Alaska (7)
Arizona (233)
Arkansas (13)
Asia (37872)
Australia (6190)
California (6366)
Canada (2059)
China (532)
Colorado (271)
Connecticut (278)
Delaware (156)
Europe (81374)
Florida (946)
Georgia (212)
Idaho (57)
Illinois (545)
India (25)
Indiana (318)
Iowa (11)
Japan (171)
Kansas (106)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (918)
Massachusetts (4728)
Michigan (223)
Minnesota (401)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (67)
New Hampshire (63)
New Jersey (1782)
New Mexico (28)
New York (1794)
North Carolina (985)
North Dakota (8)
Northern California (2801)
Ohio (208)
Oklahoma (14)
Oregon (34)
Pennsylvania (1417)
Puerto Rico (13)
Rhode Island (33)
South America (1097)
South Carolina (25)
South Dakota (1)
Southern California (2398)
Tennessee (105)
Texas (944)
United States (23853)
Utah (188)
Virginia (151)
Washington D.C. (64)
Washington State (561)
West Virginia (3)
Wisconsin (56)
699,776 Results for "arvinas inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Breast cancer
Pfizer, Arvinas Post Mixed Late-Stage Breast Cancer Data for Closely Watched PROTAC Drug
Vepdegestrant did not improve progression-free survival broadly but saw improvements in one specific patient cohort. Arvinas’ stock took a 43% tumble on the news, and analysts are downcast on the drug’s prospects.
March 11, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 2, 2025
·
24 min read
Press Releases
Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
April 29, 2025
·
1 min read
Press Releases
Arvinas to Participate in Upcoming March 2025 Investor Conferences
March 5, 2025
·
1 min read
Press Releases
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
March 28, 2025
·
4 min read
Press Releases
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting
April 22, 2025
·
4 min read
Press Releases
Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting
April 28, 2025
·
7 min read
Pharm Country
Arvinas to Participate in Upcoming Investor Conferences
Arvinas, Inc. today announced that management will participate in two upcoming investor conferences: Jefferies Global Healthcare Conference on Thursday, June 6 in New York City.
June 3, 2024
·
2 min read
Press Releases
Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2025
·
6 min read
Business
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
Arvinas, Inc. announced the appointment of Andrew Saik to the role of Chief Financial Officer and Treasurer reporting to Chairperson, Chief Executive Officer, and President, John Houston, Ph.D.
June 24, 2024
·
6 min read
1 of 69,978
Next
